JP4451059B2 - 分泌及び膜貫通ポリペプチドとそれをコードする核酸 - Google Patents

分泌及び膜貫通ポリペプチドとそれをコードする核酸 Download PDF

Info

Publication number
JP4451059B2
JP4451059B2 JP2002529483A JP2002529483A JP4451059B2 JP 4451059 B2 JP4451059 B2 JP 4451059B2 JP 2002529483 A JP2002529483 A JP 2002529483A JP 2002529483 A JP2002529483 A JP 2002529483A JP 4451059 B2 JP4451059 B2 JP 4451059B2
Authority
JP
Japan
Prior art keywords
acid sequence
pro
amino acid
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2002529483A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004526412A (ja
JP2004526412A5 (fr
Inventor
ベーカー，ケビン，ピー．
イートン，ダン，エル．
フィルバロッフ，エレン
ゴッダード，オードリー
グリマルディ，ジェー．クリストファー
ガーニー，オースティン，エル．
スミス，ヴィクトリア
ステファン，ジーン−フィリップ
ワタナベ，コリン，ケー．
ウッド，ウィリアム，アイ．
チャン，ツオーミン
フォン，シャーマン
Original Assignee
ジェネンテック インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27585542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4451059(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2000/030873 external-priority patent/WO2001040465A2/fr
Priority claimed from PCT/US2001/006520 external-priority patent/WO2001068848A2/fr
Priority claimed from PCT/US2001/017092 external-priority patent/WO2001092331A2/fr
Priority claimed from PCT/US2001/017800 external-priority patent/WO2001093983A1/fr
Priority claimed from PCT/US2001/019692 external-priority patent/WO2002000690A2/fr
Priority claimed from PCT/US2001/021066 external-priority patent/WO2002008288A2/fr
Priority claimed from PCT/US2001/021735 external-priority patent/WO2002008284A2/fr
Application filed by ジェネンテック インコーポレイテッド filed Critical ジェネンテック インコーポレイテッド
Publication of JP2004526412A publication Critical patent/JP2004526412A/ja
Publication of JP2004526412A5 publication Critical patent/JP2004526412A5/ja
Publication of JP4451059B2 publication Critical patent/JP4451059B2/ja
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002529483A 2000-09-01 2001-08-29 分泌及び膜貫通ポリペプチドとそれをコードする核酸 Expired - Lifetime JP4451059B2 (ja)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US22989600P 2000-09-01 2000-09-01
US23062100P 2000-09-05 2000-09-05
US23514700P 2000-09-22 2000-09-22
PCT/US2000/030873 WO2001040465A2 (fr) 1999-11-30 2000-11-10 Compositions et procedes de traitement de maladies d'ordre immunologique
US26187801P 2001-01-12 2001-01-12
US26191001P 2001-01-16 2001-01-16
US26215001P 2001-01-16 2001-01-16
US26193901P 2001-01-16 2001-01-16
US26439501P 2001-01-25 2001-01-25
US26642101P 2001-02-02 2001-02-02
US26762301P 2001-02-09 2001-02-09
PCT/US2001/006520 WO2001068848A2 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
US27439901P 2001-03-09 2001-03-09
US28098201P 2001-04-03 2001-04-03
US28212901P 2001-04-04 2001-04-04
US28219901P 2001-04-04 2001-04-04
US29058901P 2001-05-09 2001-05-09
PCT/US2001/017092 WO2001092331A2 (fr) 2000-05-30 2001-05-25 Compositions et methodes de traitement de maladies d'origine immune
PCT/US2001/017800 WO2001093983A1 (fr) 2000-06-02 2001-06-01 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides
PCT/US2001/019692 WO2002000690A2 (fr) 2000-06-23 2001-06-20 Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
PCT/US2001/021066 WO2002008288A2 (fr) 2000-07-20 2001-06-29 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
PCT/US2001/021735 WO2002008284A2 (fr) 2000-07-20 2001-07-09 Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese
PCT/US2001/027099 WO2002024888A2 (fr) 2000-09-01 2001-08-29 Polypeptides secretes transmembranaires et acides nucleiques codant pour ceux-ci

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006024604A Division JP2006223304A (ja) 2000-09-01 2006-02-01 分泌及び膜貫通ポリペプチドとそれをコードする核酸

Publications (3)

Publication Number Publication Date
JP2004526412A JP2004526412A (ja) 2004-09-02
JP2004526412A5 JP2004526412A5 (fr) 2010-01-28
JP4451059B2 true JP4451059B2 (ja) 2010-04-14

Family

ID=27585542

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002529483A Expired - Lifetime JP4451059B2 (ja) 2000-09-01 2001-08-29 分泌及び膜貫通ポリペプチドとそれをコードする核酸
JP2006024604A Pending JP2006223304A (ja) 2000-09-01 2006-02-01 分泌及び膜貫通ポリペプチドとそれをコードする核酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006024604A Pending JP2006223304A (ja) 2000-09-01 2006-02-01 分泌及び膜貫通ポリペプチドとそれをコードする核酸

Country Status (5)

Country Link
EP (1) EP1341814A2 (fr)
JP (2) JP4451059B2 (fr)
AU (2) AU2002216610A1 (fr)
CA (2) CA2421056A1 (fr)
WO (1) WO2002024888A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2261335T (pt) 1998-11-27 2017-09-08 Ucb Pharma Sa Composições e métodos para aumentar a mineralização óssea
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
EP1250426A2 (fr) * 1999-12-01 2002-10-23 Genentech Inc. Polypeptides transmembranaires et secretes et les acides nucleiques codant ceux-ci
US20040132021A1 (en) * 2000-06-19 2004-07-08 Wendy Balemans Osteolevin gene polymorphisms
US7094570B2 (en) 2003-03-11 2006-08-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US7268223B2 (en) 2000-09-22 2007-09-11 Wyeth Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
AU2002249948B2 (en) 2001-01-12 2007-08-23 Genetics Institute, Llc Type 2 cytokine receptor and nucleic acids encoding same
ATE464320T1 (de) * 2001-07-19 2010-04-15 Innate Pharma Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
US7585501B2 (en) 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
FR2844713A1 (fr) * 2002-09-25 2004-03-26 Exonhit Therapeutics Sa Nouvelle cible de l'angiogenese et utilisations
WO2004035789A1 (fr) * 2002-10-18 2004-04-29 Lg Life Sciences Ltd. Familles de genes associes a des cancers
MEP2808A (xx) 2003-06-16 2010-02-10 Celltech R & D Inc Antitijela specifična za sklerositin i metode za povećanje mineralizacije kostiju
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
WO2011051271A2 (fr) 2009-10-26 2011-05-05 Externautics S.P.A. Marqueurs de tumeur de la prostate et méthodes d'utilisation
WO2011051280A1 (fr) 2009-10-26 2011-05-05 Externautics S.P.A. Marqueurs de tumeurs des ovaires et leurs méthodes d'utilisation
EP2383578A1 (fr) * 2010-04-30 2011-11-02 Externautics S.p.A. Marqueur de tumeur et procédés d'utilisation correspondants
EP3195880B1 (fr) 2010-05-14 2019-11-27 Amgen Inc. Formulations d'anticorps anti-sclerostin hautement concentree
US9133272B2 (en) 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
JP2014511842A (ja) 2011-03-25 2014-05-19 アムジエン・インコーポレーテツド 抗スクレロスチン抗体結晶およびその製剤
SI2739311T1 (en) 2011-08-04 2018-07-31 Amgen Inc. Method for the treatment of bone defect defects
AU2012362898B2 (en) 2011-12-28 2017-11-09 Amgen, Inc. Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
CN104619342A (zh) 2012-07-05 2015-05-13 Ucb医药有限公司 骨疾病的治疗
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014100740A1 (fr) 2012-12-21 2014-06-26 Seattle Genetics, Inc. Anticorps anti-ntb-a et compositions et procédés associés
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
US11466079B2 (en) 2018-03-30 2022-10-11 Amgen Inc. C-terminal antibody variants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US5824504A (en) * 1996-09-26 1998-10-20 Elshourbagy; Nabil A. Human 7-transmembrane receptor and DNA
WO1999063088A2 (fr) * 1998-06-02 1999-12-09 Genentech, Inc. Proteines membranaires et acides nucleiques codant ces proteines
WO1998039448A2 (fr) * 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 nouvelles proteines secretees
JP2002512517A (ja) * 1997-03-25 2002-04-23 ジェネティックス・インスチチュート・インコーポレーテッド 分泌蛋白およびそれらをコードするポリヌクレオチド
DE19817557A1 (de) * 1998-04-09 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Ovartumorgewebe
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
EP1210418B1 (fr) * 1999-06-02 2010-08-18 Genentech, Inc. Polypeptides secretes et transmembranaires ainsi que les acides nucleiques codant pour ceux-ci

Also Published As

Publication number Publication date
JP2006223304A (ja) 2006-08-31
CA2421056A1 (fr) 2002-03-28
WO2002024888A2 (fr) 2002-03-28
EP1341814A2 (fr) 2003-09-10
JP2004526412A (ja) 2004-09-02
WO2002024888A3 (fr) 2003-07-03
AU1661002A (en) 2002-04-02
CA2632702A1 (fr) 2002-03-28
AU2002216610A1 (en) 2002-04-02

Similar Documents

Publication Publication Date Title
JP4451059B2 (ja) 分泌及び膜貫通ポリペプチドとそれをコードする核酸
US7589172B2 (en) PRO256 polypeptides
US7312303B2 (en) Anti-PRO4980 antibodies
US7294696B2 (en) PRO7168 polypeptides
US7504480B2 (en) PRO10275 polypeptides
US7297770B2 (en) PRO6496 polypeptides
US7297333B2 (en) Anti-PRO10268 antibodies
US7491797B2 (en) PRO6308 polypeptide
EP1210418B1 (fr) Polypeptides secretes et transmembranaires ainsi que les acides nucleiques codant pour ceux-ci
JP2006101881A (ja) 分泌及び膜貫通ポリペプチドとそれをコードする核酸
US7189817B2 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7304136B2 (en) PRO4407 polypeptides
US7235642B1 (en) Anti-PRO 1313 antibodies
US20060073549A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7452975B2 (en) Anti-PRO7168 antibodies
US7297769B2 (en) PRO698 polypeptides
US20060073556A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20060073557A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20060074228A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20060073554A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1300417B1 (fr) Polypeptide sécrété et transmembranaire ainsi que les acide nucléique codant pour celle-ci
US7507557B2 (en) Nucleic acids encoding PRO1375 polypeptides
EP1953173B1 (fr) Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
EP1944317A2 (fr) Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
US7425613B2 (en) PRO1375 polypeptides

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20051101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060628

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080304

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090409

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20090414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091027

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20091202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100119

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100127

R150 Certificate of patent or registration of utility model

Ref document number: 4451059

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130205

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130205

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140205

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term